ProShares Ultra Nasdaq Biotechnology Company profile
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®.The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. This ETF offers 2x daily long leverage to the broad-based NASDAQ Biotechnology Index, making it a powerful tool for investors with a bullish short-term outlook for biotechnology or pharmaceuticals companies. Investors should note that BIB’s leverage resets on a daily basis, which results in compounding of returns when held for multiple periods.Latest shares articles
UK Outlook Deteriorates as CPI Surges to 3%: Market Implications
UK inflation rose more than expected in January, putting pressure on the UK economy and the Bank of England.
10:09, 19 February 2025
Defence stocks propel DAX 40 and STOXX 600 to new highs
European stocks reach new all-time highs as increased defence spending is expected in Europe
20:02, 18 February 2025
USD forecast - third party data round up
Has the USD stabilised? Learn what’s been driving the US dollar price and whether it has any more upside potential in our USD forecast.
23:29, 17 February 2025
RBA expected to cut interest rates for the first time since 2020
The RBA is widely expected to lower the cash rate by 25 basis points to 4.10% in its first meeting of 2025. With Australia’s economy showing signs of stagnation and inflation tracking below forecasts, market expectations for a rate cut have surged.
09:11, 17 February 2025
Ratings and Reviews
Ratings and Reviews
